Inflammation and Immune System Activation After Traumatic Brain Injury

Current Neurology and Neuroscience Reports

Volumn 14, Issue 10, 2014, Pages

  Balu, Ramani ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cytokine; Damage associated molecular patterns; Inflammation; Microglia; Pattern recognition receptor; Traumatic brain injury

Indexed keywords

EID: 84905998897     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-014-0484-2     Document Type: Review

References (67)

1. Roozenbeek B, Maas AIR, Menon DK. Changing patterns in the epidemiology of traumatic brain injury. Nat Rev Neurol. 2013;9:231–6.
2. Maas AIR, Stochetti N, Bullock R. Moderate and severe traumatic brain injury in adults. Lancet Neurol. 2008;7:728–41.
3. Rosenfeld JV, Maas AIR, Bragge P, Morganti-Kossman MC, Manley GT, Gruen RL. Early management of severe traumatic brain injury. Lancet. 2012;380:1088–98.
4. Medzhitov R, Janeway C. Innate immunity. N Engl J Med. 2000;343:338–44.
5. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell. 2010;140:805–20.
6. Lamkanfi M, Dixit VM. Inflammasomes and their roles in health and disease. Annu Rev Cell Dev Biol. 2012;28:137–61.
7. Strowig T, Henao-Mejia J, Elinav E, Flavell R. Inflammasomes in health and disease. Nature. 2012;481:278–86.
8. Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med. 2013;369:840–51.
9. Chan JK, Roth J, Oppenheim JJ, Tracey KJ, Vogl T, Feldmann M, et al. Alarmins: awaiting a clinical response. J Clin Invest. 2012;122:2711–9.
10. Ransohoff RM, Kivisäkk P, Kidd G. Three or more routes for leukocyte migration into the central nervous system. Nat Rev Immunol. 2003;3:569–81.
11. Ransohoff RM, Engelhardt B. The anatomical and cellular basis of immune surveillance in the central nervous system. Nat Rev Immunol. 2012;12:623–35.
12. Weller RO, Engelhardt B, Phillips MJ. Lymphocyte targeting of the central nervous system: a review of afferent and efferent CNS-immune pathways. Brain Pathol. 1996;6:275–88.
13. Ransohoff RM, Cardona AE. The myeloid cells of the central nervous system parenchyma. Nature. 2010;468:253–62.
14. Benarroch EE. Microglia: multiple roles in surveillance, circuit shaping, and response to injury. Neurology. 2013;81:1079–88.
15. Davalos D, Grutzendler J, Yang G, Kim JV, Zuo Y, Jung S, et al. ATP mediates rapid microglial response to local brain injury in vivo. Nat Neurosci. 2005;8:752–8.
16. Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science. 2005;308:1314–8.
17. Wake H, Moorhouse AJ, Jinno S, Kohsaka S, Nabekura J. Resting microglia directly monitor the functional state of synapses in vivo and determine the fate of ischemic terminals. J Neurosci. 2009;29:3974–80.
18. Stephan AH, Barres BA, Stevens B. The complement system: an unexpected role in synaptic pruning during development and disease. Annu Rev Neurosci. 2012;35:369–89.
19. Parkhurst CN, Yang G, Ninan I, Savas JN, Yates 3rd JR, Lafaille JJ, et al. Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor. Cell. 2013;155:1596–609. Inducible expression of diphtheria toxin in microglia using transgenic technology allowed the authors to selectively ablate microglial cells in adult mice. Removing microglial cells caused deficits in learning that are mediated by brain-derived neurotrophic factor secreted by microglial cells.
20. Halle A, Hornung V, Petzold GC, Stewart CR, Monks BG, Reinheckel T, et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol. 2008;9:857–65.
21. Kaindl AM, Degos V, Peineau S, Gouadon E, Chhor V, Loron G, et al. Activation of microglial N-methyl-D-aspartate receptors triggers inflammation and neuronal cell death in the developing and mature brain. Ann Neurol. 2012;72:536–49. This is an intriguing study showing that microglia express functional NMDA receptors, and that microglial NMDA receptor activation induces cytokine release. Selective knockout of NMDA receptors in microglia protected mice from NMDA-receptor-mediated damage caused by intracerebral ibotenate injection.
22. de Rivero Vaccari JP, Dietrich WD, Keane RW. Activation and regulation of cellular inflammasomes: gaps in our knowledge for central nervous system injury. J Cereb Blood Flow Metab. 2014;34:369–75.
23. Başkaya MK, Rao AM, Doğan A, Donaldson D, Dempsey RJ. The biphasic opening of the blood-brain barrier in the cortex and hippocampus after traumatic brain injury in rats. Neurosci Lett. 1997;226:33–6.
24. Holmin S, Mathiesen T. Biphasic edema development after experimental brain contusion in rat. Neurosci Lett. 1995;194:97–100.
25. Shlosberg D, Benifla M, Kaufer D, Friedman A. Blood-brain barrier breakdown as a therapeutic target in traumatic brain injury. Nat Rev Neurol. 2010;6393-403.
26. Kirchhoff C, Stegmaier J, Bogner V, Buhmann S, Mussack T, Kreimeier U, et al. Intrathecal and systemic concentration of NT-proBNP in patients with severe traumatic brain injury. J Neurotrauma. 2006;23:943–9.
27. Lenzlinger PM, Marx A, Trentz O, Kossmann T, Morganti-Kossmann MC. Prolonged intrathcal release of soluble Fas following severe traumatic brain injury in humans. J Neuroimmunol. 2002;122:167–74.
28. Tomkins O, Shelef I, Kaizerman I, Eliushin A, Afawi Z, Misk A, et al. Blood-brain barrier disruption in post-traumatic epilepsy. J Neurol Neurosurg Psychiatry. 2008;79:774–7.
29. Holmin S, Mathiesen T, Shetye J, Biberfeld P. Intracerebral inflammatory response to experimental brain contusion. Acta Neurochir. 1995;132:110–9.
30. Holmin S, Mathiesen T. Long-term intracerebral inflammatory response after experimental focal brain injury in rat. Neuroreport. 1999;10:1889–91.
31. Holmin S, Söderlund J, Biberfeld P, Mathiesen T. Intracerebral inflammation after human brain contusion. Neurosurgery. 1998;42:291–8.
32. Wang KY, Yu GF, Zhang ZY, Huang Q, Dong XD. Plasma high-mobility group box 1 levels and prediction of outcome in patients with traumatic brain injury. Clin Chim Acta. 2012;413:1737–41.
33. Laird MD, Shields JS, Sukumari-Ramesh S, Kimbler DE, Fessler RD, Shakir B et al. High mobility group box protein-1 promotes cerebral edema after traumatic brain injury via activation of Toll-like receptor 4. Glia. 2014;26-38. This study showed NMDA-receptor-dependent HMGB-1 release from neurons after experimental TBI. HMGB1 binding to TLR4 induced cerebral edema by upregulating aquaporin 4 expression.
34. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol. 2005;5:331–42.
35. Harris HE, Andersson U, Pisetsky DS. HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease. Nat Rev Rheumatol. 2012;8:195–202.
36. Marchi N, Bazarian JJ, Puvenna V, Janigro M, Ghosh C, Zhong J, et al. Consequences of repeated blood-brain barrier disruption in football players. PLoS One. 2013;8:e56805.
37. Zhang Z, Zoltewicz JS, Mondello S, Newsom KJ, Yang Z, Yang B, et al. Human traumatic brain injury induces autoantibody response against glial fibrillary acidic protein and its breakdown products. PLoS One. 2014;9:e92698.
38. Liu HD, Li W, Chen ZR, Hu YC, Zhang DD, Shen W, et al. Expression of the NLRP3 inflammasome in cerebral cortex after traumatic brain injury in a rat model. Neurochem Res. 2013;38:2072–83.
39. Yu ZQ, Zha JH. Genetic ablation of Toll-like receptor 2 reduces secondary brain injury caused by cortical contusion in mice. Ann Clin Lab Sci. 2012;42:26–33.
40. Ahmad A, Crupi R, Campolo M, Genovese T, Esposito E, Cuzzocrea S. Absence of TLR4 reduces neurovascular unit and secondary inflammatory process after traumatic brain injury in mice. PLoS One. 2013;8:e57208.
41. Helmy A, De Simoni MG, Guilfoyle MR, Carpenter KL, Hutchinson PJ. Cytokines and innate inflammation in the pathogenesis of human traumatic brain injury. Prog Neurobiol. 2011;95:352–72.
42. Woodcock T, Morganti-Kossmann MC. The role of markers of inflammation in traumatic brain injury. Front Neurol. 2013;4:18.
43. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med. 2009;361:888–98.
44. Pleines UE, Stover JF, Kossmann T, Trentz O, Morganti-Kossmann MC. Soluble ICAM-1 in CSF coincides with the extent of cerebral damage in patients with severe traumatic brain injury. J Neurotrauma. 1998;15:399–409.
45. Roberts I, Yates D, Sandercock P, Farrell B, Wasserberg J, Lomas G, et al. Effect of intravenous corticosteroids on death within 14 days in 10008 adults with clinically significant head injury (MRC-CRASH trial): randomized placebo-controlled trial. Lancet. 2004;364:1321–8.
46. Edwards P, Arango M, Balica L, Cottingham R, El-Sayed H, Farrell B, et al. Final results of MRC CRASH, a randomized placebo controlled trial of intravenous corticosteroids in adults with head injury—outcomes at 6 months. Lancet. 2005;365:1957–9.
47. 4 integrins as therapeutic targets in autoimmune disease. N Engl J Med. 2003;348:68–72.
48. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2003;348:15–23.
49. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899–910.
50. Fabene PF, Navarro Mora G, Martinello M, Rossi B, Merigo F, Ottoboni L, et al. A role for leukocyte-endothelial adhesion mechanisms in epilepsy. Nat Med. 2008;14:1377–83.
51. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med. 2005;353:369–74.
52. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med. 2005;353:375–81.
53. Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366:1870–80.
54. Massberg S, von Andrian UH. Fingolimod and sphingosine-1-phosphate—modifiers of lymphocyte migration. N Engl J Med. 2006;355:1088–91.
55. Pelletier D, Hafler DA. Fingolimod for multiple sclerosis. N Engl J Med. 2012;366:339–47.
56. Helmy A, Guilfoyle MR, Carpenter KL, Pickard JD, Menon DK, Hutchison PJ. Recombinant human interleukin-1 receptor antagonist in severe traumatic brain injury: a phase II trial randomized control trial. J Cereb Blood Flow Metab. 2014;34:845–51. This is an exciting trial in humans demonstrating that subcutaneous administration of IL-1 receptor antagonist after TBI is safe, reaches therapeutic levels in the brain interstitial space, and alters cytokine profiles.
57. Clausen F, Hånell A, Björk M, Hillered L, Mir AK, Gram H, et al. Neutralization of interleukin-1β modifies the inflammatory response and improves histological and cognitive outcome following traumatic brain injury in mice. Eur J Neurosci. 2009;30:385–96.
58. Clausen F, Hånell A, Björk M, Hillered L, Mir AK, Gram H, et al. Neutralization of interleukin-1beta reduces cerebral edema and tissue loss and improves late cognitive outcome following traumatic brain injury in mice. Eur J Neurosci. 2011;34:110–23.
59. Sanchez-Meija RO, Ona VO, Li M, Friedlander RM. Minocycline reduces traumatic brain injury-mediated caspase-1 activation, tissue damage, and neurological dysfunction. Neurosurgery. 2001;48:1393–9.
60. Homsi S, Federico F, Croci N, Palmier B, Plotkine M, Marchand-Leroux C, et al. Minocycline effects on cerebral edema: relations with inflammatory and oxidative stress markers following traumatic brain injury in mice. Brain Res. 2009;1291:122–32.
61. Plane JM, Shen Y, Pleasure DE, Deng W. Prospects for minocycline neuroprotection. Arch Neurol. 2010;67:1442–8.
62. Lopez-Rodriguez AB, Siopi E, Finn DP, Marchand-Leroux C, Garcia-Segura LM, Jafarian-Tehrani M, et al. CB1 and CB2 cannabinoid receptor antagonists prevent minocycline-induced neuroprotection following traumatic brain injury in mice. Cereb Cortex. 2013. doi:10.1093/cercor/bht202.
63. Okuma Y, Liu K, Wake H, Zhang J, Maruo T, Date I, et al. Anti-high mobility group box-1 antibody therapy for traumatic brain injury. Ann Neurol. 2012;72:373–84. Administering a monoclonal anti-HMGB1 antibody after fluid percussion injury caused a dramatic reduction in lesion volume and cerebral edema, as well as significant functional improvement. This study paves the way for human trials investigating whether inhibiting HMGB1 signaling may improve outcomes after TBI.
64. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science. 1999;285:248–51.
65. Katzenberger RJ, Loewen CA, Wassarman DR, Petersen AJ, Ganetzky B, Wassarman DA. A Drosophila model of closed head injury. Proc Natl Acad Sci U S A. 2013. doi:10.1073/pnas.1316895110. The authors developed a simple, reproducible model of TBI in Drosophila, paving the way for forward genetic screens that can identify genes that may protect against secondary brain injury. Susceptibility to TBI in flies was shown to depend on genetic background and components of the innate immune system. Similar approaches have identified numerous important clinical targets in a variety of other diseases.
66. Günther M, Al Nimer F, Gahm C, Piel F, Mathiesen T. iNOS-mediated secondary inflammatory response differs between rat strains following experimental brain contusion. Acta Neurochir. 2012;154:689–97.
67. Roth TL, Nayak D, Atanasijevic T, Koretsky AP, Latour LL, McGavern DB. Transcranial amelioration of inflammation and cell death after brain injury. Nature. 2014;505223-8. The authors used in vivo multiphoton microscopy to study the dynamics of immune cell activation after a concussion-type injury in mice. They showed early changes in microglial morphology followed by infiltration of neutrophils. Adding blockers of reactive oxygen species to the surface of the thinned skull remarkably blocked most of the inflammatory response.